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Individuals with the rare para-Bombay phenotype have inherited 
defects in producing H associated with FUT1 and/or FUT2 genes. 
We report a case of blood group discrepancy in a para-Bombay 
patient from a tertiary care hospital of eastern India. A 31-year-
old woman with rheumatic heart disease presented with fatigue 
and breathlessness and was then scheduled for valvuloplasty, for 
which a blood transfusion request was sent to the blood center. 
During pre-transfusion testing, red blood cell (RBC) testing 
showed group O, and serum testing showed strong reactivity 
with group B RBCs, weak reactivity with group O RBCs, and 
very weak reactivity with group A RBCs. Saliva inhibition testing 
and enzyme treatment of RBCs concluded the patient to be of “Ah 
para-Bombay” phenotype. The patient’s Lewis phenotype was 
Le(a–b+). This patient’s serum also had cold-reacting anti-IH 
along with anti-B. This case report highlights the importance of 
performing an advanced immunohematologic workup, including 
adsorption, elution, enzyme treatment, and saliva inhibition 
testing for identification of weak A or B subgroups as well as 
the rare para-Bombay blood group, when routine ABO typing, 
using forward and reverse grouping, is inconclusive. Accurate 
identification of blood group helps in preventing transfusion-
related adverse events and encouraging safe transfusion practice. 
Immunohematology 2021;37:160–164. DOI: 10.21307/
immunohematology-2021-026.
Key Words: para-Bombay phenotype, anti-IH, FUT1 gene, 
FUT2 gene, H-deficient phenotype, saliva inhibition test
Bombay and para-Bombay are rare, autosomal-recessive, 
H-deficient blood group phenotypes. Individuals with these 
phenotypes are unable to produce type 2H, which is the 
precursor for A and B.1 The molecular basis of these phenotypes 
is due to mutations in FUT1 (H gene) and/or FUT2, also known 
as the secretor gene. The important differentiating feature 
between these phenotypes is that para-Bombay individuals 
are homozygous for a non-functional FUT1 and have at least 
one functional FUT2, having the genotype of either hh, Se/Se 
or hh, Se/se, making them secretors and responsible for the 
formation of H in the saliva or other tissues like gastrointestinal 
or genitourinary tissues. Occasionally, from the secretions, H, 
A, and/or B may sometimes get adsorbed onto the red blood 
cell (RBC) surface. Thus, para-Bombay individuals carry 
negligible amounts of H, A, and/or B on their RBCs, which 
may or may not be identified by routine serologic testing.2 Only 
a very few cases of individuals with the para-Bombay blood 
group presenting with a blood group discrepancy are reported. 
The para-Bombay phenotypes are even more rare than the 
Bombay phenotype, estimated at a ratio of 1:15.3 Moreover, 
the actual incidence of para-Bombay is still unknown in the 
Indian population. Blood grouping is challenging in such 
individuals, and proper understanding and performance of a 
detailed immunohematologic workup in such individuals play 
a vital role when determining appropriate transfusion therapy.
Case Report
A 31-year-old woman from a remote village in the state of 
Odisha, in eastern India, presented to the cardiology outpatient 
department with complaints of fatigue and breathlessness. She 
had been in treatment for rheumatic heart disease with mitral 
stenosis for the past few years. During her present visit, she was 
admitted to the intensive care unit for unstable blood pressure 
and tachycardia. After further evaluation, the cardiology team 
planned for balloon valvuloplasty, and a blood transfusion 
request was sent to the transfusion medicine department 
for any emergency requirement during the intervention. The 
patient was a mother of four children, all born via normal 
delivery, and was neither aware of her blood group or had any 
transfusions until this date. No blood group details of any of 
her family members were available.
Immunohematologic Workup
Patient blood grouping was done via a gel card (Matrix 
Octoplus Forward and Reverse Grouping Card with Sub 
Grouping; Tulip Diagnostics [P] Ltd., Goa, India). Her RBCs 
showed no reactivity with anti-A or anti-B, but showed 
strong reactivity with anti-D. But her serum testing showed 
1+ reactivity with group O RBCs, no reactivity with group 
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A RBCs, and strong reactivity with group B RBCs. Thus, 
forward typing showed her RBCs as group O and reverse 
typing supported her being an A of some type. Blood grouping 
was repeated with washed RBCs and the same blood grouping 
card, which gave the same results, along with no reactivity 
with anti-H (Fig. 1A). The standard test tube method (forward 
typing performed using commercially available antisera from 
Tulip Diagnostic [P] Ltd. and reverse typing performed using 
in-house prepared 3–5% pooled group A, group B, and group 
O RBCs) at both room temperature (RT) and 4°C revealed 
similar results in forward typing but weak reactivity with 
the group O and group A RBCs along with strong reactivity 
with group B RBCs in the reverse typing  at RT incubation. 
The same in-house prepared pooled RBCs were used in both 
phases of reverse typing. However, the strength of reactivity 
with group O and group A RBCs was enhanced when 
incubated at 4°C for 1 hour (Fig. 1B and C). The autologous 
control at 4°C and at RT was negative (not shown in Fig. 1). 
Hence, based on the results summarized in Table 1, forward 
typing showed a picture of Bombay/para-Bombay phenotype, 
and reverse typing suggested the presence of anti-B, along 
with the possibility of anti-H, anti-IH, or other cold-reacting 
antibodies in the patient’s serum. Serum typing was performed 
at 37°C and antihuman globulin (AHG) phase by using AHG 
(Tulip Diagnostic [P] Ltd.) and showed the same strength with 
group B RBCs, weak reactivity with group O RBCs, and no 
reactivity with group A RBCs, suggesting the possibility of 
an immunoglobulin (Ig)G and/or (Ig)M component of anti-B 
with high thermal amplitude along with anti-H or anti-IH 
with wide thermal range. There was no pattern of reactivity 
identifying an antibody specificity observed with commercially 
available reagent RBCs for antibody screening (ID-DiaCell 
I-II-III; Bio-Rad, Cressier, Switzerland), since the testing 
showed panreactivity at 4°C, RT, and the AHG phase. The 
serum was then tested with RBCs of different phenotypes for 
differentiation and identification of cold-reacting antibodies, 
using the method described in the AABB technical manual.4 
The reactivity pattern fit with the anti-IH pattern (Table 2). 
Furthermore, the patient’s serum was tested with saliva 
containing H substance, but the patient’s anti-IH did not show 
any inhibition by the H substance. This finding is a typical 
picture of anti-IH, which, unlike anti-H, is not inhibited by 
salivary H substance.5 Therefore, it was concluded that the 
patient’s serum had anti-B, along with anti-IH.
The patient’s RBC phenotype was found to be Le(a–b+) 
using anti-Lea and anti-Leb murine monoclonal antisera 
(Immucor, Norcross, GA), although the strength of reactivity 
Table 1. Results of forward and reverse typing in gel card and 
standard test tube method
Method
Forward typing Reverse typing
Anti-A Anti-B Anti-D Anti-AB Anti-H O RBCs A RBCs B RBCs
Matrix gel 
system*








0 0 4+ 0 0 3+ 4+ 4+
RBCs = red blood cells; RT = room temperature.
* Testing performed using Matrix Octoplus Forward and Reverse Grouping 
Card with Sub Grouping; Tulip Diagnostics (P) Ltd.
Table 2. Results of reactivity pattern of cold antibodies with 
different RBCs
Serum reactivity observed with: At RT At 4°C
Group O adult RBCs (O I) 1+ 3+
Group O cord RBCs (O i) 0 0
Group A1 adult RBCs (A1 I) 1+ 4+
Enzyme-treated group O RBCs 1+ 3+
Bombay (Oh) RBCs 0 0
Autologous RBCs 0 0 to weak
RBCs = red blood cells; RT = room temperature.
Fig. 1 (A) Blood group discrepancy using gel cards (Matrix 
Octoplus Forward and Reverse Grouping Card with Sub Grouping; 
Tulip Diagnostics [P] Ltd.). (B) Serum grouping by tube method (by 
in-house prepared pooled red blood cells) at room temperature. (C) 
Serum grouping by tube method (by in-house prepared pooled red 
blood cells) at 4°C.
A
CB
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was very weak (Fig. 2A). Secretor status was also performed 
by saliva inhibition study according to the AABB technical 
manual.6 The patient was a secretor of A and H substance, but 
the presence of A on RBCs could not be demonstrated by cold 
adsorption and heat elution methods, even after best efforts 
were tried, like increasing the cell-to-serum ratio and overnight 
incubation. Papain (LIQUIPAP; Tulip Diagnostics [P] Ltd.) 
treatment of the patient’s RBCs, per AABB recommendations,7 
showed augmented reactivity against both polyclonal sera 
derived from in-house healthy blood donors and monoclonal 
anti-A (Tulip Diagnostics [P] Ltd.), (Fig. 2B and C). Thus, the 
patient’s blood group was identified and confirmed to be Ah 
para-Bombay.
Discussion
The H on RBCs is synthesized by α-(1,2)-fucosyltrans-
ferase enzyme regulated by two different but closely linked 
genes, FUT1 and FUT2. FUT1 (H gene) regulates expression 
on RBCs, and FUT2 (Se gene) is accountable for H in secretions 
in different tissues. Among ABO carbohydrate blood group 
systems, Bombay and para-Bombay are rare, autosomal-
recessive, H-deficient phenotypes due to homozygous 
amorphous alleles of the FUT1 gene (hh). In these individuals, 
the type 2 precursor chain remains unchanged, prohibiting 
them from synthesizing the “H structure,” which is the 
precursor for A and B.8 RBCs of these individuals are typically 
serologically negative for H, A, and B along with the presence 
of naturally occurring anti-H, anti-A, and anti-B in their 
plasma. The distinguishing feature of para-Bombay is the 
presence of soluble type 1 ABH substance in mucosa and 
secretions. Serologically, the para-Bombay phenotypes can be 
distinguished from Bombay phenotype as outlined in Table 
3. The FUT2 gene present in para-Bombay converts type 1 
precursor chain to type 1H, which on further action by A or 
B enzymes is converted to type 1A or type 1B, respectively. 
Trace amounts of ABH on RBCs may be detectable because 
of adsorption of these antigens from plasma; but in some 
instances, even adsorption and elution studies cannot detect 
them.8 We also encountered no or very negligible expression 
of A on the RBCs, resulting in a blood group discrepancy in 
this para-Bombay case. Although the patient was a secretor for 
A and H substances, adsorption and elution studies could not 
demonstrate the presence of A on RBCs. Only by the enzyme 
enhancement method was the presence of A established.
We noted a very weak strength of reactivity while 
phenotyping for Leb with Leb antisera. (Immucor), Lewis 
antigens are not intrinsic to RBCs and are adsorbed into the 
membrane of RBCs from the plasma. This fact explains why 
Lewis typing of RBCs is difficult and sometimes confusing 
because of weak hemagglutination caused by low titer or low 
specificity of the reagents. The distribution and expression of 
Lewis phenotypes in a population also vary with ethnicity, 
gender, and demographic region.9,10
The ability of para-Bombay individuals to express ABH 
in tissues like genitourinary epithelium or gastrointestinal 
epithelium draws special attention when ABO mismatched 
solid organ transplantation is being considered. Townamchai 
et al.11 reported that a group AB para-Bombay kidney donor 
was unintentionally misclassified as blood group O. If that mis-
classification had not been corrected, transplanting the donor 
tissue of this group AB para-Bombay into a group O blood 
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Fig. 2 (A) Le(a–b+) phenotype (secretor). (B) Saliva secretor status showed secretion of A and H substances. (C) Enzyme-treated patient 
red blood cells (Papain, LIQUIPAP; Tulip Diagnostics [P] Ltd.) showed reactivity with anti-A.
A B C
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group patient would have resulted in detrimental hyperacute 
rejection ensuing immediate intravascular thrombosis and 
sudden allograft loss due to the reaction between anti-A or 
anti-B of the recipient’s serum and A or B on the para-Bombay 
donor’s kidney epithelial cells. Hence, successful ABO-
incompatible renal transplantation in such a group O recipient 
required pre-transplantation desensitization because of the 
donor’s ABO group being group AB para-Bombay.11
The molecular basis of occurrence of Bombay and para-
Bombay phenotypes are proposed to possess mutations in 
FUT1 and FUT2, more frequently nonsense and missense 
mutations.12 There are more than 30 FUT1 and 5 FUT2 
alleles associated with weak H expression and 25 FUT1 and 
22 FUT2 alleles associated with loss of H expression.13 Some 
well-known mutations for FUT2 are c.385A>T (p.Ile129Phe) 
in FUT2*01W.02 alleles in the Asian population and nonsense 
mutation c.428 G>A (p.Trp142Ter) found in the FUT2*01N.02 
allele and reported in African and European populations.14 In 
addition to naturally occurring anti-A and/or anti-B, para-
Bombay individuals can also produce anti-H, anti-IH, or 
both. These antibodies are predominantly of IgM type and 
exhibit a broad thermal range (4–37°C) as we encountered 
in this case.15 Determining the presence of these antibodies 
is important because they are sometimes potent enough to 
cause rapid intravascular RBC destruction.16 Anti-IH, a weak 
H-like antibody, is almost always present in the serum of these 
individuals. This antibody is nonreactive with cord RBCs 
and is not inhibited by secretor saliva.8 Unlike anti-H and 
anti-I, it reacts only in the presence of both H and I together. 
Agglutination with group O Iadult RBCs and no agglutination 
with group O icord RBCs and Oh Iadult Bombay RBCs suggests 
the specificity of anti-IH in our patient.4 The titer of the cold 
antibody in this patient was 8 at 37°C and RT and 32 at 4°C. 
Since the cold antibody is reacting at 37°C, it is considered 
clinically significant. In view of transfusion therapy, this 
patient could be transfused with only Bombay or para-Bombay 
blood group RBCs due to preformed antibodies in the serum. 
In this case, the patient underwent the intervention without 
any need for transfusion.
Consequently, systematic investigation of any blood group 
discrepancy with detailed immunohematologic workup has 
established a vital role in planning transfusion therapy in such 
rare phenotype individuals.
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